Mitochondria-Targeted Peptide SS-31 Protects Pancreatic Islet Cells and Improves Diabetes

The mitochondria-targeted peptide SS-31 prevented pancreatic islet cell apoptosis, preserved insulin secretion, and improved diabetes outcomes in animal models — protecting the insulin-producing cells that diabetes destroys.

Thomas, Dolca A et al.·Journal of the American Society of Nephrology : JASN·2007·Moderate EvidenceAnimal StudyAnimal Study
RPEP-01295Animal StudyModerate Evidence2007RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

SS-31 (mitochondria-targeted peptide) prevented mitochondrial depolarization and apoptosis in pancreatic islet cells, preserved glucose-stimulated insulin secretion, and improved glycemic control in diabetic animals — protecting the beta-cells that diabetes progressively destroys.

Key Numbers

How They Did This

animal-study study.

Why This Research Matters

Relevant for opioid-peptides, diabetes, neuroprotection.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding SS-31 (mitochondria-targeted peptide) prevented mitochondrial depolarization and apoptosis in pancreatic islet cells, preserved glucose-stimulated ins
Evidence Grade:
moderate evidence.
Study Age:
Published in 2007.
Original Title:
Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function.
Published In:
Journal of the American Society of Nephrology : JASN, 18(1), 213-22 (2007)
Database ID:
RPEP-01295

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Mitochondria-Targeted Peptide SS-31 Protects Pancreatic Islet Cells and Improves Diabetes

What was found?

The mitochondria-targeted peptide SS-31 prevented pancreatic islet cell apoptosis, preserved insulin secretion, and improved diabetes outcomes in animal models — protecting the insulin-producing cells that diabetes destroys.

Read More on RethinkPeptides

Cite This Study

RPEP-01295·https://rethinkpeptides.com/research/RPEP-01295

APA

Thomas, Dolca A; Stauffer, Craig; Zhao, Kesheng; Yang, Hua; Sharma, Vijay K; Szeto, Hazel H; Suthanthiran, Manikkam. (2007). Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function.. Journal of the American Society of Nephrology : JASN, 18(1), 213-22.

MLA

Thomas, Dolca A, et al. "Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function.." Journal of the American Society of Nephrology : JASN, 2007.

RethinkPeptides

RethinkPeptides Research Database. "Mitochondrial targeting with antioxidant peptide SS-31 preve..." RPEP-01295. Retrieved from https://rethinkpeptides.com/research/thomas-2007-mitochondrial-targeting-with-antioxidant

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.